Diabetes technology

1 trial
  • 2019iDCL / DCLP3Hybrid closed-loop insulinIn 168 patients aged 14–71 with type 1 diabetes, hybrid closed-loop insulin delivery (Control-IQ) improved time-in-range and HbA1c compared with sensor-augmented pump therapy.